Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2015 16:05 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin

NOVATO, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
January 06, 2015 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia

NOVATO, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
January 05, 2015 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at the J.P. Morgan Healthcare Conference

Novato, CA, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases,...
December 15, 2014 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

NOVATO, Calif., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
December 03, 2014 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at the Oppenheimer Healthcare Conference

Novato, CA, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases,...
November 10, 2014 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update

NOVATO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
November 04, 2014 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at the Credit Suisse Annual Healthcare Conference

Novato, CA, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases,...
October 30, 2014 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Granted EU Orphan Drug Designation for KRN23 for the Treatment of X-Linked Hypophosphatemia

Novato, CA, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases,...
October 27, 2014 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Granted Orphan Drug Designation for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome

Novato, CA, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases,...
October 13, 2014 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society

NOVATO, Calif., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...